Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
B cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies. However, a sub-type of B cells named regulatory B cells or Bregs has recently shown capacities to prevent or cure arthritis in mouse models. Bregs have also been identified in humans.
B cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies. However, a sub-type of B cells named regulatory B cells or Bregs has recently shown capacities to prevent or cure arthritis in mouse models. Bregs have also been identified in humans. Main objective: To study Bregs abnormalities in patients with rheumatoid arthritis (RA) at different stages of the disease compared to subjects with mechanical pathologies.Secondary objectives:- To evaluate the specificity of any abnormalities identified in RA by studying Bregs in patients with other autoimmune or other inflammatory joint diseases.- To evaluate the effect of biological and synthetic treatments on Bregs in patients with RA. - To assess whether the rate of Bregs before treatment is predictive of response to biological and synthetic treatments.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| RA patients | Patients affected by Rheumatoid arthritis. | ||
| Control | Subjects affected by either :
|
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of Bregs levels | The levels of Bregs will be assessed in patients with RA and compared to subjects with mechanical pathologies. | 30 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change of Bregs levels after therapy | The levels of Bregs will be assessed in patients who will start a therapy within the framework of their usual follow-up. | 30 months |
Not provided
Inclusion Criteria:
For RA patients and control patients:
For RA patients:
For control patients:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients and controls will be recruited in the Immuno-rheumatology Service of the University Hospital of Montpellier.
They will be recruited during consultations or hospitalizations, when a blood sample is planned within the framework of their usual follow-up.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jacques Morel, MD, PhD | Contact | 0033467338710 | j-morel@chu-montpellier.fr | |
| Claire Daien, MD | Contact | 0033673042406 | cdaien@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Jacques Morel, MD, PhD | University Hospital, Montpellier | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lapeyronie Hospital | Recruiting | Montpellier | 34295 | France |
Not provided
Not provided
Not provided
Not provided
Comparison of Bregs levels
Lymphocytes will be analyzed from :
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| D010003 | Osteoarthritis |
| D008180 | Lupus Erythematosus, Systemic |
| D012859 | Sjogren's Syndrome |
| D045743 | Scleroderma, Diffuse |
| D013166 | Spondylitis |
| D006073 | Gout |
| D013122 | Spinal Diseases |
| D002805 | Chondrocalcinosis |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D014987 | Xerostomia |
| D012466 | Salivary Gland Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D015352 | Dry Eye Syndromes |
| D007766 | Lacrimal Apparatus Diseases |
| D005128 | Eye Diseases |
| D012595 | Scleroderma, Systemic |
| D012871 | Skin Diseases |
| D001850 | Bone Diseases, Infectious |
| D007239 | Infections |
| D001847 | Bone Diseases |
| D000070657 | Crystal Arthropathies |
| D011686 | Purine-Pyrimidine Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided